Special Considerations in the Management of HIV-Infected Patients From Minority Communities
Summary
- WHO guidelines recommend giving oral tenofovir DF–containing PrEP with other preventive strategies to patients with substantial risk of HIV infection including subgroups of MSM and transgender women[WHO 2016]
- Several clinical trials enrolling MSM and transgender women have demonstrated high efficacy of emtricitabine/tenofovir DF given as PrEP[McCormack 2016; Molina 2015]
- Adherence is generally high in patients engaging in high risk behaviors[Liu 2016; Hosek 2017]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content